Ateroskleroz: Primer ve Sekonder Korunma

Abstract

Aterosklerotik sürecin sonuçlarıyla ilişkili hastalıklar oldukça yaygın morbidite ve mortalite nedenlerini oluşturmaktadır. Kardiyovasküler hastalıklar olarak bilinen bu durumlar arasında koroner arter hastalığı, serebrovasküler hastalıklar, periferik damar hastalıkları ve aort anevrizmaları yer almaktadır. Değiştirilebilir risk faktörlerinin hedefler doğrultusunda ortadan kaldırılması ya da düzenlenmesi ile bu hastalıkların engellenebilmesi ya da hastalığın ilerlemesinin durdurulabilmesi mümkündür. Kardiyovasküler hastalığı olmayan kişilerde bilinen risk faktörleriyle mücadeleye başlarken öncellikle kişinin taşıdığı toplam risk düzeyi belirlenmeli ve belirlenen hedefe göre yalnızca yaşam tarzı değişikliği ya da ek olarak ilaç tedavisi planlanmalıdır. Kardiyovasküler olay geçirmiş kişilerde ise risk faktör modifikasyonunun yanında bazı ilaçların rutin kullanımı gerekebilmektedir.

Keywords

• Ateroskleroz
• Koroner olay
• Risk faktörleri
• Korunma

References

1. Bartecchi, C., MacKenzie, T.D., Schrier, R.W., 1994. The human costs of tobacco use. N. Engl. J. Med. 330, 907-912.
2. British Cardiac Society, 2000. Joint British recommendations on prevention of coronary heart disease in clinical practice: Summary. British Hyperlipidaemia Association, British Hypertension Society, British Diabetic Association. B.M.J. 320, 705-708.
3. Collins, R., Peto, R., MacMahon, S., Hebert, P., Fiebach, N.H., Eberlein, K.A., Godwin, J., Qizilbash, N., Taylor, J.O., Hennekens, C.H., 1990. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: Overview of randomized drug trials in their epidemiological context. Lancet. 335, 827-838.
4. Franco, O., De Laet, C., Peeters, A., Jonker, J., Mackenbach, J., Nusselder, W., 2005. Effects of physical activity on life expectancy with cardio- vascular disease. Arch. Intern. Med. 165, 2355-2360.
5. Gotto, A.M. Jr., 2005. Review of primary and secondary prevention trials with lovastatin, pravastatin, and simvastatin. Am. J. Cardiol. 96, 34- 38.
6. He, K., Song, Y., Daviglus, M.L., Liu, K., Van Horn, L., Dyer, A.R., Greenland, P., 2004. Accumulated evidence on fish consumption and coro- nary heart disease mortality: A meta-analysis of cohort studies. Circulation. 109, 2705-2711.
7. Hebert, P.R., Moser, M., Mayer, J., Glynn, R.J., Hennekens, C.H., 1993. Recent evidence on drug therapy of mild to moderate hypertension and decreased incidence of coronary heart disease. Arch. Intern. Med. 153, 578-581.
8. Hu, F.B., Stampfer, M.J., Manson, J.E., Rimm, E., Colditz, G.A., Rosner, B.A., Hennekens, C.H., Willett, W.C., 1997. Dietary fat intake and the risk of coronary heart disease in women. N. Eng. J. Med. 337, 1491-1499.

9. Joshipura, K.J., Hu, F.B., Manson, J.E., Stampfer, M.J., Rimm, E.B., Speizer, F.E., Colditz, G., Ascherio, A., Rosner, B., Spiegelman, D., Willett, W.C., 2001. The effect of fruit and vegetable intake on risk for coronary heart disease. Ann. Intern. Med. 134, 1106-1114.
10. Kurth, T., Moore, S.C., Gaziano, J.M., Kase, C.S., Stampfer, M.J., Berger, K., Buring, J.E, 2006. Healthy lifestyle and the risk of stroke in women. Arch. Intern. Med. 166, 1403-1409.
11. Kuulasmaa, K., Tunstall, P.H., Dobson, A., Fortmann, S., Sans, S., Tolonen, H., Evans, A., Ferrario, M., Tuomilehto, J., 2000. Estimation of contribution of changes in classic risk factors to trends in coronary-event rates across the WHO MONICA Project populations. Lancet. 355, 675-687.
12. Lam, T., He, Y., 1997. Passive smoking and coronary heart disease: A brief review. Clin. Exp. Pharmacol. Physiol. 24, 993-996.
13. MacKenzie, T., Bartecchi, C.E., Schrier, R.W., 1994. The human costs of tobacco use. N. Engl. J. Med. 330, 975-980.
14. Mansia, G., De Backer, G., Dominiczak, A., Cifkova, R., Fagard, R., Germano, G., Grassi, G., Heagerty, A.M., Kjeldsen, S.E., Laurent, S., Narkiewicz, K., Ruilope, L., Rynkiewicz, A., Schmieder, R.E., Struijker Boudier, H.A., Zanchetti, A.; European Society of Hypertension; European Society of Cardiology., 2007. ESH-ESC Guidelines for the management of arterial hypertension: The task force for the manage- ment of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (E.S.C.). Blood Press. 16, 135-232.
15. Mensink, R.P., Katan, M.B., 1992. Effect of dietary fatty acids on serum lipids and lipoproteins. A meta-analysis of 27 trials. Arterioscler Thromb. 12, 911-919.
16. Petersen, S., Peto, V., Rayner, M., Leal, J., Luengo, F.R., Gray, A., 2005. European Cardiovascular Statistics: 2005 edition. London: British Heart Foundation.
17. Pyorala, K., De Backer, G., Graham, I., Poole-Wilson, P., Wood, D., 1994. Prevention of coronary heart disease in clinical practice: Recommen- dations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Atherosclerosis. 110, 121-161.
18. Sever, P.S., Dahlöf, B., Poulter, N.R., Wedel, H., Beevers, G., Caulfield M., Collins, R., Kjeldsen, S.E., Kristinsson, A., McInnes, G.T., Mehlsen, J., Nieminen, M., O'Brien, E., Ostergren, J., ASCOT investigators., 2003. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial. Lancet. 361, 1149-1158.
19. Shepherd, J., Cobbe, S.M., Ford, I., Isles, C.G., Lorimer, A.R., MacFarlane, P.W., McKillop, J.H., Packard, C.J., 1995. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med. 333, 1301-1307.
20. Smith, S.C., Allen, J., Blair, S.N., Bonow, R.O., Brass, L.M., Fonarow, G.C., Grundy, S.M., Hiratzka, L., Jones, D., Krumholz, H.M., Mosca, L., Pasternak, R.C., Pearson, T., Pfeffer, M.A,. Taubert, K.A.; AHA/ACC; National Heart, Lung, and Blood Institute., 2006. AHA/ACC guide- lines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: Endorsed by the National Heart, Lung, and Blood Institute. Circulation. 113, 2363-2372.
21. Staessen, J.A., Wang, J.G., Thijs, L., 2001. Cardiovascular protection and blood pressure reduction: A meta-analysis. Lancet 358, 1305-1315.
22. Thavendiranathan, P., Bagai, A., Brookhart,. M.A., Choudhry, N.K., 2006. Primary prevention of cardiovascular diseases with statin therapy: A meta-analysis of randomized controlled trials. Arch. Intern. Med. 166, 2307-2313.
23. UK Prospective Diabetes Study (UKP.D.S.) Group., 1998. Intensive blood-glucose control with sulphonylureas or insulin compared with con- ventional treatment and risk of complications in patients with type 2 diabetes (UKP.D.S. 33). Lancet. 352, 837-853.
24. Vasan, R.S., Larson, M.G., Leip, E.P., Evans, J.C., O'Donnell, C.J., Kannel, W.B., Levy, D., 2001. Impact of high-normal blood pressure on the risk of cardiovascular disease. N. Engl. J. Med. 345, 1291-1297.
25. WHO, 2002. WHO Publications. The World Health Report.
26. Wood, D., De Backer, G., Faergeman, O., Graham, I., Mancia, G., Pyorala, K., 1998. Prevention of coronary heart disease in clinical practice: Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Atherosclerosis. 140, 199-270.
27. Yusuf, S., Hawken, S., Ounpuu, S., Dans, T., Avezum, A., Lanas, F., McQueen, M., Budaj, A., Pais, P., Varigos, J., Lisheng, L., INTERHEART Study Investigators, 2004. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTER- HEART study): Case-control study. Lancet. 364, 937-952.